Biotech Values

[mcbio]

With Multaq (dronedarone) on the market, and MRK's oral Vernakalant in development, not sure anyone else would be interested in budiodarone because of huge cost associated with potential phase III program.

I thought ARYX had designed budiodarone to have some advantages over Multaq though. Also, even with potential competition from oral Vernakalant, I thought ARYX was targeting a large market for the drug where there would be plenty of room for a few entrants. Presumably someone will come in now and scoop up budiodarone for next to nothing.